License deal for preclinical S-365598 continues longstanding R&D relationship between ViiV and stakeholder Shionogi, which also developed dolutegravir and cabotegravir.

Innovent is paying the Danish biotech $20m upfront for the China rights to the mid-stage PDE4 inhibitor that is being developed for psoriasis, atopic dermatitis and hidradenitis suppurativa. 

Precision is looking ahead to market access challenges for its off-the-shelf CAR-T and in vivo gene-editing therapies.

Two years into her tenure as the head of Menarini, Elcin Barker Ergun has already inked two major cancer deals with the acquisition of Stemline and a key licensing pact with Radius Health. The future for the Italian group is bright, she explained to Scrip in an exclusive interview.

Amgen’s former chief information officer Diana McKenzie highlights the inroads made by technology firms in healthcare and how life science companies can adapt from them while leveraging core capabilities at scale.

CEO David Meeker spoke with Scrip about how the company is targeting its drug, Imcivree, across potentially dozens of rare genetic diseases of obesity.

As more countries adopt heterologous boosting of COVID-19 vaccines in a bid to improve supplies and/or immunity while reducing side effects, vaccines expert and ex-Hilleman CEO Davinder Gill talks to Scrip in an audio interview on the challenges of the strategy and of the disease becoming endemic.

What on earth would make a biotech company change the primary endpoint half way through a Phase III program and not discuss it with the FDA? There are at least two scenarios, neither of them good.

As India gets set to resume COVID-19 vaccine diplomacy from October, a new rule which will require Indians visiting UK who are fully vaccinated with AstraZeneca partner Serum Institute’s vaccine to undergo quarantine has sparked a row. Meanwhile, Indian companies await a nod from the WHO for wider acceptance of their COVID-19 vaccines.

Encouraging new data for Spectrum/Hanmi’s poziotinib presented at ESMO may increase the chances of approval for the pan-HER inhibitor as a possible first-line therapy for NSCLC with the HER2 exon 20 insertion mutation, although the patient population is limited.

License deal for preclinical S-365598 continues longstanding R&D relationship between ViiV and stakeholder Shionogi, which also developed dolutegravir and cabotegravir.

The company, which has reported no R&D successes outside of its CGRP inhibitor platform, said verdiperstat did not differentiate from placebo on any endpoints in multiple system atrophy.